Payment overview · 2025
General Payments
$177.62
6 reported records · 4 companies
Healthcare provider profile · identity verified
Glenton W Davis, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SELMA, AL · NPI 1962475046
Verified facts
What the public records show
CMS Open Payments records show Glenton W Davis, M.D. received $177.62 in general payments during 2025 across 6 reported records.
Astellas Pharma US Inc accounted for 45.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 405 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $79.99 | 45.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.66 | 28.0% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.09 | 18.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.88 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $97.63 | 5 |
| Education | $79.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $49.66 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $32.09 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 143 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 405 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
143 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
405 | 86 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 2568 | 292 |
| Amlodipine Besylate | Amlodipine Besylate | 1481 | 402 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1017 | 273 |
| Losartan Potassium | Losartan Potassium | 829 | 225 |
| Simvastatin | Simvastatin | 638 | 164 |
| Famotidine | Famotidine | 603 | 166 |
| Metformin Hcl | Metformin Hcl | 476 | 135 |
| Metoprolol Tartrate | Metoprolol Tartrate | 476 | 110 |
| Potassium Chloride | Potassium Chloride | 444 | 128 |
| Gabapentin | Gabapentin | 416 | 79 |
| Furosemide | Furosemide | 405 | 110 |
| Jardiance | Empagliflozin | 405 | 86 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 352 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 351 | 98 |
| Eliquis | Apixaban | 348 | 45 |
| Carvedilol | Carvedilol | 320 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 308 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 278 | 60 |
| Meloxicam | Meloxicam | 276 | 81 |
| Clopidogrel | Clopidogrel Bisulfate | 269 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 252 | 67 |
| Colchicine | Colchicine | 242 | 56 |
| Lisinopril | Lisinopril | 241 | 64 |
| Donepezil Hcl | Donepezil Hcl | 240 | 52 |
| Alprazolam | Alprazolam | 233 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 229 | 61 |
| Lorazepam | Lorazepam | 228 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 222 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 216 | 61 |
| Mirtazapine | Mirtazapine | 209 | 55 |
| Omeprazole | Omeprazole | 184 | 56 |
| Azithromycin | Azithromycin | 178 | 129 |
| Diclofenac Sodium | Diclofenac Sodium | 174 | 69 |
| Baclofen | Baclofen | 172 | 64 |
| Clonidine Hcl | Clonidine Hcl | 171 | 41 |
| Glimepiride | Glimepiride | 149 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 148 | 46 |
| Farxiga | Dapagliflozin Propanediol | 143 | 27 |
| Mounjaro | Tirzepatide | 139 | 22 |
| Allopurinol | Allopurinol | 137 | 36 |
| Doxazosin Mesylate | Doxazosin Mesylate | 137 | 39 |
| Tramadol Hcl | Tramadol Hcl | 134 | 29 |
| Trazodone Hcl | Trazodone Hcl | 134 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 65 |
| Valsartan | Valsartan | 128 | 34 |
| Alendronate Sodium | Alendronate Sodium | 120 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 28 |
| Labetalol Hcl | Labetalol Hcl | 114 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 112 | 36 |
| Fluconazole | Fluconazole | 112 | 63 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 111 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 109 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 20 |
| Divalproex Sodium | Divalproex Sodium | 105 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 34 |
| Ozempic | Semaglutide | 103 | 20 |
| Meclizine Hcl | Meclizine Hcl | 100 | 22 |
| Linzess | Linaclotide | 98 | 25 |
| Prednisone | Prednisone | 94 | 46 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 93 | 72 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 26 |
| Glipizide | Glipizide | 92 | 31 |
| Januvia | Sitagliptin Phosphate | 92 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 92 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 90 | 26 |
| Chlorthalidone | Chlorthalidone | 87 | 24 |
| Buspirone Hcl | Buspirone Hcl | 85 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 85 | 22 |
| Pregabalin | Pregabalin | 85 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 82 | 28 |
| Spironolactone | Spironolactone | 80 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 72 | 14 |
| Memantine Hcl | Memantine Hcl | 72 | suppressed |
| Latanoprost | Latanoprost | 69 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 69 | 50 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 67 | 14 |
| Levetiracetam | Levetiracetam | 66 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 65 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 17 |
| Telmisartan | Telmisartan | 65 | 17 |
| Montelukast Sodium | Montelukast Sodium | 60 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 59 | 21 |
| Sucralfate | Sucralfate | 59 | 23 |
| Testosterone Cypionate | Testosterone Cypionate | 55 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 54 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 47 |
| Enalapril Maleate | Enalapril Maleate | 53 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 13 |
| Atenolol | Atenolol | 52 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 48 | 18 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | suppressed |
| Topiramate | Topiramate | 45 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 44 | 15 |
| Amoxicillin | Amoxicillin | 43 | 37 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 42 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Hydrocortisone | Hydrocortisone | 39 | 24 |
| Lovastatin | Lovastatin | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Rexulti | Brexpiprazole | 39 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Mupirocin | Mupirocin | 36 | 30 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | 11 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 33 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 32 | 32 |
| Clindamycin Hcl | Clindamycin Hcl | 32 | 24 |
| Naproxen | Naproxen | 31 | 11 |
| Scopolamine | Scopolamine | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Olanzapine | Olanzapine | 30 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 21 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 26 | suppressed |
| Humulin R | Insulin Regular, Human | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 24 |
| Multaq | Dronedarone Hcl | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Humalog | Insulin Lispro | 24 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 16 |
| Rybelsus | Semaglutide | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 21 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Haloperidol | Haloperidol | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Phenobarbital | Phenobarbital | 20 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Calcium Acetate | Calcium Acetate | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | 15 |
| Nitroglycerin Patch | Nitroglycerin | 18 | suppressed |
| Novolin R | Insulin Regular, Human | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 17 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 15 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Travoprost | Travoprost | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | 13 |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $177.62 · 6 records | Astellas Pharma US Inc | FANAPT, FARXIGA, JARDIANCE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error